Alex Fraser, Patient Access Lead with Grow Pharma, on the recently-launched ‘Open Cannabis’ campaign
THE truth is there are a huge number of patients with chronic pain and other symptoms who are unaware that cannabis medicines are a legal option for them.
These people deserve to have access to the right information so they can make the best choice for their health – this is why I’m a passionate supporter of the Open Cannabis campaign.
I was diagnosed with Crohn’s disease a little over ten years ago. At the time, I had no idea what this would mean for me. Looking back, I know now why my doctors were so solemn when they delivered the diagnosis.
Crohn’s is one of a plethora of chronic (long-term) conditions that can cause constant, severe pain for which there are few prescribed treatments. Fewer still that are tolerable for a lifetime. Like many immune disorders, there is no cure.
For the next seven years, I was forced to break the law in order to mitigate my pain, whilst also campaigning for legal access to the one thing that helped – cannabis.
Had I not found cannabis early on I honestly don’t know if I would still be here. Chronic pain plays a role in one in 10 suicides and about 30% of those who suffer with chronic pain have suicidal thoughts. I was certainly one of them.
You can imagine my joy when, in November 2018, the UK Government rescheduled cannabis medicines, enabling access to a wide range of medicines, via private prescriptions, for many different conditions.
UK Law Change ‘Too Late For Me’
The change came too late for me. I had bowel resection surgery in 2017 and have been in remission since. But Crohn’s doesn’t go away and my symptoms could return at any time.
Knowing that I can now go to a specialist doctor and discuss cannabis medicines in a legal, prescribed context, is a reassurance that, should my disease return, I won’t be forced back to criminality.
With my current role as Patient Access Lead with Grow Pharma, a leading supplier of cannabis medicines, I am more informed than most on how to access a prescription.
Others are not so fortunate…Patients of all ages with many serious conditions – including fibromyalgia, arthritis, IBD and multiple sclerosis (to name but a few) – are often unaware that cannabis medicines present a legal alternative for them.
With nearly half of people over 55 also suffering with chronic pain, this is an issue that we cannot ignore. Polling undertaken by the Open Cannabis campaign has shown that these age groups are actually very open to considering cannabis medicines as a treatment option, but don’t know how to access them.
Public-Facing Awareness Campaign
Open Cannabis is a public-facing information and awareness campaign that primarily targets people who do not yet use cannabis medicines, rather than existing patients.
The website has helpful resources for patients, doctors and a useful ‘find a clinic’ feature for those looking at taking the next step. The campaign is supported by organisations from across the cannabis industry including patient groups, doctor groups, clinics and suppliers.
The campaign hopes that increasing general awareness of cannabis medicines, the symptoms they are used to treat and how to access them, will build momentum that will in turn help lower the price of medication making it more cost effective for patients and more likely to be considered for the NHS.
NHS access is the aim of many in the medical cannabis industry, myself and Grow Pharma are no exception. Private systems currently present an alternative in the absence of NHS access, but are in no way a barrier, more an enabler, for progress toward this important end goal.
Suppliers like Grow are reducing costs, building reliable supply chains, educating healthcare professionals and helping to develop the evidence base required by NICE for NHS access with both clinical trials and real-world data gathering schemes.
All of this sounds very positive, but won’t help patients if they remain in the dark, uninformed of the current situation and the options available to them. This is why Open Cannabis is so important.
It may appear as simply a single point of reference for information on cannabis medicines, but to me, as a patient and advocate, it represents a call to action: That we NEED to start having these all-important conversations, informing patients, doctors and the general public, removing judgement and stigma and progressing access in a way that works for those who need it.
Healthcare professionals, the cannabis industry and existing patients need to help educate the wider public, to ensure that everyone that might stand to benefit from cannabis medicines has access to the right information to make the best decisions for themselves and their health.
SOMAÍ Pharmaceuticals Signs Distribution Deal with Grow Pharma for UK’s Most Comprehensive Range of Cannabis-Based Medicines SOMAÍ Pharmaceuticals ("SOMAÍ"), an...
It’s Time To ‘Open Cannabis’ Prescriptions To NHS Patients
Alex Fraser, Patient Access Lead with Grow Pharma, on the recently-launched ‘Open Cannabis’ campaign
THE truth is there are a huge number of patients with chronic pain and other symptoms who are unaware that cannabis medicines are a legal option for them.
These people deserve to have access to the right information so they can make the best choice for their health – this is why I’m a passionate supporter of the Open Cannabis campaign.
I was diagnosed with Crohn’s disease a little over ten years ago. At the time, I had no idea what this would mean for me. Looking back, I know now why my doctors were so solemn when they delivered the diagnosis.
Crohn’s is one of a plethora of chronic (long-term) conditions that can cause constant, severe pain for which there are few prescribed treatments. Fewer still that are tolerable for a lifetime. Like many immune disorders, there is no cure.
For the next seven years, I was forced to break the law in order to mitigate my pain, whilst also campaigning for legal access to the one thing that helped – cannabis.
Had I not found cannabis early on I honestly don’t know if I would still be here. Chronic pain plays a role in one in 10 suicides and about 30% of those who suffer with chronic pain have suicidal thoughts. I was certainly one of them.
You can imagine my joy when, in November 2018, the UK Government rescheduled cannabis medicines, enabling access to a wide range of medicines, via private prescriptions, for many different conditions.
UK Law Change ‘Too Late For Me’
The change came too late for me. I had bowel resection surgery in 2017 and have been in remission since. But Crohn’s doesn’t go away and my symptoms could return at any time.
Knowing that I can now go to a specialist doctor and discuss cannabis medicines in a legal, prescribed context, is a reassurance that, should my disease return, I won’t be forced back to criminality.
With my current role as Patient Access Lead with Grow Pharma, a leading supplier of cannabis medicines, I am more informed than most on how to access a prescription.
Others are not so fortunate…Patients of all ages with many serious conditions – including fibromyalgia, arthritis, IBD and multiple sclerosis (to name but a few) – are often unaware that cannabis medicines present a legal alternative for them.
With nearly half of people over 55 also suffering with chronic pain, this is an issue that we cannot ignore. Polling undertaken by the Open Cannabis campaign has shown that these age groups are actually very open to considering cannabis medicines as a treatment option, but don’t know how to access them.
Public-Facing Awareness Campaign
Open Cannabis is a public-facing information and awareness campaign that primarily targets people who do not yet use cannabis medicines, rather than existing patients.
The website has helpful resources for patients, doctors and a useful ‘find a clinic’ feature for those looking at taking the next step. The campaign is supported by organisations from across the cannabis industry including patient groups, doctor groups, clinics and suppliers.
The campaign hopes that increasing general awareness of cannabis medicines, the symptoms they are used to treat and how to access them, will build momentum that will in turn help lower the price of medication making it more cost effective for patients and more likely to be considered for the NHS.
NHS access is the aim of many in the medical cannabis industry, myself and Grow Pharma are no exception. Private systems currently present an alternative in the absence of NHS access, but are in no way a barrier, more an enabler, for progress toward this important end goal.
Suppliers like Grow are reducing costs, building reliable supply chains, educating healthcare professionals and helping to develop the evidence base required by NICE for NHS access with both clinical trials and real-world data gathering schemes.
All of this sounds very positive, but won’t help patients if they remain in the dark, uninformed of the current situation and the options available to them. This is why Open Cannabis is so important.
It may appear as simply a single point of reference for information on cannabis medicines, but to me, as a patient and advocate, it represents a call to action: That we NEED to start having these all-important conversations, informing patients, doctors and the general public, removing judgement and stigma and progressing access in a way that works for those who need it.
Healthcare professionals, the cannabis industry and existing patients need to help educate the wider public, to ensure that everyone that might stand to benefit from cannabis medicines has access to the right information to make the best decisions for themselves and their health.
What to know about the insurance landscape in cannabis
Next PostWeekly Chronicle Issue 1: Inside the Cannabis ‘Entourage Effect’
Peter
Related Posts
Related Posts
It Is High Time for a Renaissance in the UK Cannabis Industry
Written for Business of Cannabis by Andrew Pepper, Partner at business restructuring and consultancy firm ReSolve Advisory. In January...
Chill Brands CEO Suspended Amid Allegations Of ‘Use of Inside Information’, SynBiotic Buys Croatian CBD Maker, & Hellenic Secures Funding
Chill Brands Chill Brands has seen its share price dive by nearly 40% this week after news emerged that...
Tikun Olam Europe Leads the Change in Greece’s Rapidly Evolving Medical Cannabis Landscape
Cannabis Associations in Germany Face New Restrictions in Push to Prevent Commercialisation
#ReleaseOurMeds Campaign Launches to Protect the Rights of Patients to Access Their Medicine
Jersey Hemp Wins Watershed Legal Battle Against UK Home Office Which Threatened Entire CBD Industry
CONNECT
Related Posts
Related Posts
It Is High Time for a Renaissance in the UK Cannabis Industry
Written for Business of Cannabis by Andrew Pepper, Partner at business restructuring and consultancy firm ReSolve Advisory. In January...
Chill Brands CEO Suspended Amid Allegations Of ‘Use of Inside Information’, SynBiotic Buys Croatian CBD Maker, & Hellenic Secures Funding
Chill Brands Chill Brands has seen its share price dive by nearly 40% this week after news emerged that...
Tikun Olam Europe Leads the Change in Greece’s Rapidly Evolving Medical Cannabis Landscape
Earlier this year, Greece became the latest EU country to make medical cannabis products available to patients. In February 2024,...
Cannabis Associations in Germany Face New Restrictions in Push to Prevent Commercialisation
The German government is reportedly set to push through legislation that would tighten the already strict rules around cultivation associations....
#ReleaseOurMeds Campaign Launches to Protect the Rights of Patients to Access Their Medicine
Release is launching a vital initiative. We are launching the #ReleaseOurMeds campaign to protect the rights of patients to access...
Recent Posts
Related Posts
Somaí Pharmaceuticals Introduces UK To The Most Complete Cannabis-based Product Portfolio Following A Distribution Deal
SOMAÍ Pharmaceuticals Signs Distribution Deal with Grow Pharma for UK’s Most Comprehensive Range of Cannabis-Based Medicines SOMAÍ Pharmaceuticals ("SOMAÍ"), an...
European Round-Up: German Medical Cannabis Fightback, UK Cannabis ‘Colonialism’, United Nations Gets Into Hemp etc…
THE German cannabis industry, patients groups and doctors have launched a fightback against proposals which would have a detrimental impact...
UK Companies Warn Ban On Medical Cannabis Exports Will Damage Future Investment
AS Brains Bioceuticals unveiled a significant expansion of its UK production facilities, it has warned that any future investment is...
French Senators Petition Macron’s Government For Urgent Cannabis Reform
OVER 30 senators from the Socialist, Ecologist and Republican group have called for the launch of a consultation process to...
British People Open To Using Medical Cannabis – Yet Majority Unaware They Can Access It On Prescription
A NEW national survey of 4,000 people has highlighted the need to improve awareness of cannabis as a medicine. Key...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags